The human NADPH oxidase: Primary and secondary defects impairing the respiratory burst function and the microbicidal ability of phagocytes

Scandinavian Journal of Immunology

Volumn 73, Issue 5, 2011, Pages 420-427

  de Oliveira Junior, E B ^a   Bustamante, J ^b   Newburger, P E ^c   Condino Neto, A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; MICROBICIDE; RAC2 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

AUTOSOMAL RECESSIVE DISORDER; CHRONIC GRANULOMATOUS DISEASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HUMAN; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; MUTATIONAL ANALYSIS; NONHUMAN; PHAGOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RESPIRATORY FUNCTION; REVIEW; X CHROMOSOME;

EID: 79953031472     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2010.02501.x     Document Type: Review

References (95)

1. Nauseef WM. Biological roles for the NOX family NADPH oxidases. J Biol Chem 2008;283:16961-5.
2. Rossi F, Zatti M. Biochemical aspects of phagocytosis in polymorphonuclear leucocytes. NADH and NADPH oxidation by the granules of resting and phagocytizing cells. Experientia 1964;20:21-3.
3. Klebanoff SJ. Myeloperoxidase. Proc Assoc Am Physicians 1999;111:383-9.
4. Babior BM, Kipnes RS, Curnutte JT. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 1973;52:741-4.
5. Royer-Pokora B, Kunkel LM, Monaco AP et al. Cloning the gene for the inherited disorder chronic granulomatous disease on the basis of its chromosomal location. Cold Spring Harb Symp Quant Biol 1986;51 (Pt 1):177-83.
6. Parkos CA, Dinauer MC, Walker LE, Allen RA, Jesaitis AJ, Orkin SH. Primary structure and unique expression of the 22-kilodalton light chain of human neutrophil cytochrome b. Proc Natl Acad Sci U S A 1988;85:3319-23.
7. Volpp BD, Nauseef WM, Donelson JE, Moser DR, Clark RA. Cloning of the cDNA and functional expression of the 47-kilodalton cytosolic component of human neutrophil respiratory burst oxidase. Proc Natl Acad Sci U S A 1989;86:7195-9.
8. Leto TL, Lomax KJ, Volpp BD et al. Cloning of a 67-kD neutrophil oxidase factor with similarity to a noncatalytic region of p60c-src. Science 1990;248:727-30.
9. Zhan S, Vazquez N, Wientjes FB et al. Genomic structure, chromosomal localization, start of transcription, and tissue expression of the human p40-phox, a new component of the nicotinamide adenine dinucleotide phosphate-oxidase complex. Blood 1996;88:2714-21.
10. Roos D, van Bruggen R, Meischl C. Oxidative killing of microbes by neutrophils. Microbes Infect 2003;5:1307-15.
11. Segal AW, Jones OT, Webster D, Allison AC. Absence of a newly described cytochrome b from neutrophils of patients with chronic granulomatous disease. Lancet 1978;2:446-9.
12. Parkos CA, Allen RA, Cochrane CG, Jesaitis AJ. Purified cytochrome b from human granulocyte plasma membrane is comprised of two polypeptides with relative molecular weights of 91, 000 and 22, 000. J Clin Invest 1987;80:732-42.
13. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007;87:245-313.
14. Condino-Neto A, Newburger PE. NADPH oxidase activity and cytochrome b558 content of human Epstein-Barr-virus-transformed B lymphocytes correlate with expression of genes encoding components of the oxidase system. Arch Biochem Biophys 1998;360:158-64.
15. Dinauer MC, Lekstrom-Himes JA, Dale DC. Inherited neutrophil disorders: molecular basis and new therapies. Hematology (Am Soc Hematol Educ Program) 2000:303-18.
16. Newburger PE, Ezekowitz RA. Cellular and molecular effects of recombinant interferon gamma in chronic granulomatous disease. Hematol Oncol Clin North Am 1988;2:267-76.
17. Newburger PE, Dai Q, Whitney C. In vitro regulation of human phagocyte cytochrome b heavy and light chain gene expression by bacterial lipopolysaccharide and recombinant human cytokines. J Biol Chem 1991;266:16171-7.
18. Eklund EA, Luo W, Skalnik DG. Characterization of three promoter elements and cognate DNA binding protein(s) necessary for IFN-gamma induction of gp91-phox transcription. J Immunol 1996;157:2418-29.
19. Kakar R, Kautz B, Eklund EA. JAK2 is necessary and sufficient for interferon-gamma-induced transcription of the gene encoding gp91PHOX. J Leukoc Biol 2005;77:120-7.
20. Berendes H, Bridges RA, Good RA. A fatal granulomatosus of childhood: the clinical study of a new syndrome. Minn Med 1957;40:309-12.
21. Bridges RA, Berendes H, Good RA. A fatal granulomatous disease of childhood; the clinical, pathological, and laboratory features of a new syndrome. AMA J Dis Child 1959;97:387-408.
22. Holland SM. Chronic granulomatous disease. Clin Rev Allergy Immunol 2010;38:3-10.
23. Roos D, Kuhns DB, Maddalena A et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis 2010;45:246-65.
24. Rae J, Newburger PE, Dinauer MC et al. X-Linked chronic granulomatous disease: mutations in the CYBB gene encoding the gp91-phox component of respiratory-burst oxidase. Am J Hum Genet 1998;62:1320-31.
25. Barese CN, Copelli SB, De Matteo E et al. Molecular characterization of a novel splice site mutation within the CYBB gene leading to X-linked chronic granulomatous disease. Pediatr Blood Cancer 2005;44:420-2.
26. Dinauer MC, Curnutte JT, Rosen H, Orkin SH. A missense mutation in the neutrophil cytochrome b heavy chain in cytochrome-positive X-linked chronic granulomatous disease. J Clin Invest 1989;84:2012-6.
27. Bolscher BG, de Boer M, de Klein A, Weening RS, Roos D. Point mutations in the beta-subunit of cytochrome b558 leading to X-linked chronic granulomatous disease. Blood 1991;77:2482-7.
28. Patino PJ, Perez JE, Lopez JA et al. Molecular analysis of chronic granulomatous disease caused by defects in gp91-phox. Hum Mutat 1999;13:29-37.
29. Winkelstein JA, Marino MC, Johnston RB et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000;79:155-69.
30. Agudelo-Florez P, Prando-Andrade CC, Lopez JA et al. Chronic granulomatous disease in Latin American patients: clinical spectrum and molecular genetics. Pediatr Blood Cancer 2006;46:243-52.
31. Johnston RB. Clinical aspects of chronic granulomatous disease. Curr Opin Hematol 2001;8:17-22.
32. Condino-Neto A, Muscara MN, Bellinati-Pires R et al. Effect of therapy with recombinant human interferon-gamma on the release of nitric oxide by neutrophils and mononuclear cells from patients with chronic granulomatous disease. J Interferon Cytokine Res 1996;16:357-64.
33. Marciano BE, Wesley R, De Carlo ES et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis 2004;39:692-9.
34. Bianchi M, Hakkim A, Brinkmann V et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 2009;114:2619-22.
35. Kang EM, Linton G, Theobald N, O'Brien SA, Hilligoss D, Malech HL. Treatment of infections in patients with X-linked chronic granulomatous disease with gene therapy. Blood (ASH Annual Meeting Abstracts) 2007;110:504.
36. Ott MG, Schmidt M, Schwarzwaelder K et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12:401-9.
37. Ott MG, Seger R, Stein S, Siler U, Hoelzer D, Grez M. Advances in the treatment of Chronic Granulomatous Disease by gene therapy. Curr Gene Ther 2007;7:155-61.
38. Stein S, Ott MG, Schultze-Strasser S et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010;16:198-204.
39. Hacein-Bey-Abina S, Hauer J, Lim A et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010;363:355-64.
40. Holmes B, Quie PG, Windhorst DB, Good RA. Fatal granulomatous disease of childhood. An inborn abnormality of phagocytic function. Lancet 1966;1:1225-8.
41. Babior BM. NADPH oxidase. Curr Opin Immunol 2004;16:42-7.
42. Odell EW, Segal AW. Killing of pathogens associated with chronic granulomatous disease by the non-oxidative microbicidal mechanisms of human neutrophils. J Med Microbiol 1991;34:129-35.
43. Reeves EP, Lu H, Jacobs HL et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 2002;416:291-7.
44. Roos D, Kuhns DB, Maddalena A et al. Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update). Blood Cells Mol Dis 2010;44:291-9.
45. Matute JD, Arias AA, Wright NA et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 2009;114:3309-15.
46. Williams DA, Tao W, Yang F et al. Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. Blood 2000;96:1646-54.
47. Curnutte JT. Classification of chronic granulomatous disease. Hematol Oncol Clin North Am 1988;2:241-52.
48. Baehner RL, Kunkel LM, Monaco AP et al. DNA linkage analysis of X chromosome-linked chronic granulomatous disease. Proc Natl Acad Sci U S A 1986;83:3398-401.
49. Skalnik DG, Dorfman DM, Perkins AS et al. Targeting of transgene expression to monocyte/macrophages by the gp91-phox promoter and consequent histiocytic malignancies. Proc Natl Acad Sci U S A 1991;88:8505-9.
50. Kautz B, Kakar R, David E, Eklund EA. SHP1 protein-tyrosine phosphatase inhibits gp91PHOX and p67PHOX expression by inhibiting interaction of PU.1, IRF1, interferon consensus sequence-binding protein, and CREB-binding protein with homologous Cis elements in the CYBB and NCF2 genes. J Biol Chem 2001;276:37868-78.
51. Lindsey S, Zhu C, Lu YF, Eklund EA. HoxA10 represses transcription of the gene encoding p67phox in phagocytic cells. J Immunol 2005;175:5269-79.
52. Lien LL, Lee Y, Orkin SH. Regulation of the myeloid-cell-expressed human gp91-phox gene as studied by transfer of yeast artificial chromosome clones into embryonic stem cells: suppression of a variegated cellular pattern of expression requires a full complement of distant cis elements. Mol Cell Biol 1997;17:2279-90.
53. Roos D, de Boer M, Kuribayashi F et al. Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood 1996;87:1663-81.
54. Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. Curr Opin Immunol 2003;15:578-84.
55. Smith RM, Curnutte JT. Molecular basis of chronic granulomatous disease. Blood 1991;77:673-86.
56. Dinauer MC, Pierce EA, Bruns GA, Curnutte JT, Orkin SH. Human neutrophil cytochrome b light chain (p22-phox). Gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. J Clin Invest 1990;86:1729-37.
57. de Boer M, de Klein A, Hossle JP et al. Cytochrome b558-negative, autosomal recessive chronic granulomatous disease: two new mutations in the cytochrome b558 light chain of the NADPH oxidase (p22-phox). Am J Hum Genet 1992;51:1127-35.
58. Casimir CM, Bu-Ghanim HN, Rodaway AR, Bentley DL, Rowe P, Segal AW. Autosomal recessive chronic granulomatous disease caused by deletion at a dinucleotide repeat. Proc Natl Acad Sci USA 1991;88:2753-7.
59. Vazquez N, Lehrnbecher T, Chen R et al. Mutational analysis of patients with p47-phox-deficient chronic granulomatous disease: the significance of recombination events between the p47-phox gene (NCF1) and its highly homologous pseudogenes. Exp Hematol 2001;29:234-43.
60. Gorlach A, Lee PL, Roesler J et al. A p47-phox pseudogene carries the most common mutation causing p47-phox-deficient chronic granulomatous disease. J Clin Invest 1997;100:1907-18.
61. Greve B, Hoffmann P, Vonthein R et al. NCF1 gene and pseudogene pattern: association with parasitic infection and autoimmunity. Malar J 2008;7:251.
62. van de Vosse E, van Wengen A, van Geelen JA, de Boer M, Roos D, van Dissel JT. A novel mutation in NCF1 in an adult CGD patient with a liver abscess as first presentation. J Hum Genet 2009;54:313-6.
63. Heyworth PG, Noack D, Cross AR. Identification of a novel NCF-1 (p47-phox) pseudogene not containing the signature GT deletion: significance for A47 degrees chronic granulomatous disease carrier detection. Blood 2002;100:1845-51.
64. Patino PJ, Rae J, Noack D et al. Molecular characterization of autosomal recessive chronic granulomatous disease caused by a defect of the nicotinamide adenine dinucleotide phosphate (reduced form) oxidase component p67-phox. Blood 1999;94:2505-14.
65. Nunoi H, Iwata M, Tatsuzawa S et al. AG dinucleotide insertion in a patient with chronic granulomatous disease lacking cytosolic 67-kD protein. Blood 1995;86:329-33.
66. Accetta D, Syverson G, Bonacci B et al. Human phagocyte defect caused by a Rac2 mutation detected by means of neonatal screening for T cell lymphopenia. J Allergy Clin Immunol 2010; doi: .
67. Ambruso DR, Knall C, Abell AN et al. Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proc Natl Acad Sci U S A 2000;97:4654-9.
68. Vignais PV. The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell Mol Life Sci 2002;59:1428-59.
69. Stasia MJ, Li XJ. Genetics and immunopathology of chronic granulomatous disease. Semin Immunopathol 2008;30:209-35.
70. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
71. Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006;210:171-86.
72. Pennington KN, Taylor JA, Bren GD, Paya CV. IkappaB kinase-dependent chronic activation of NF-kappaB is necessary for p21(WAF1/Cip1) inhibition of differentiation-induced apoptosis of monocytes. Mol Cell Biol 2001;21:1930-41.
73. Moynagh PN. The NF-kappaB pathway. J Cell Sci 2005;118:4589-92.
74. Condino-Neto A, Whitney C, Newburger PE. Dexamethasone but not indomethacin inhibits human phagocyte nicotinamide adenine dinucleotide phosphate oxidase activity by down-regulating expression of genes encoding oxidase components. J Immunol 1998;161:4960-7.
75. Luengo-Blanco M, Prando C, Bustamante J et al. Essential role of nuclear factor-kappaB for NADPH oxidase activity in normal and anhidrotic ectodermal dysplasia leukocytes. Blood 2008;112:1453-60.
76. Nishikomori R, Akutagawa H, Maruyama K et al. X-linked ectodermal dysplasia and immunodeficiency caused by reversion mosaicism of NEMO reveals a critical role for NEMO in human T-cell development and/or survival. Blood 2004;103:4565-72.
77. Puel A, Picard C, Ku CL, Smahi A, Casanova JL. Inherited disorders of NF-kappaB-mediated immunity in man. Curr Opin Immunol 2004;16:34-41.
78. Medvedev AE, Lentschat A, Kuhns DB et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J Exp Med 2003;198:521-31.
79. Chapel H, Puel A, von Benuth H, Picard C, Casanova JL. Shigella sonnei meningitis due to interleukin-1 receptor-associated kinase-4 deficiency: first association with a primary immune deficiency. Clin Infect Dis 2005;40:1227-31.
80. Picard C, Puel A, Bonnet M et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003;299:2076-9.
81. Ku CL, von Bernuth H, Picard C et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 2007;204:2407-22.
82. Singh A, Zarember KA, Kuhns DB, Gallin JI. Impaired priming and activation of the neutrophil NADPH oxidase in patients with IRAK4 or NEMO deficiency. J Immunol 2009;182:6410-7.
83. Pacquelet S, Johnson JL, Ellis BA et al. Cross-talk between IRAK-4 and the NADPH oxidase. Biochem J 2007;403:451-61.
84. Luzzatto L, Battistuzzi G. Glucose-6-phosphate dehydrogenase. Adv Hum Genet 1985;14:217-329.
85. Ho HY, Cheng ML, Chiu DT. G6PD - an old bottle with new wine. Chang Gung Med J 2005;28:606-12.
86. WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ 1989; 67:601-11.
87. Mason PJ. New insights into G6PD deficiency. Br J Haematol 1996;94:585-91.
88. Spolarics Z, Siddiqi M, Siegel JH et al. Increased incidence of sepsis and altered monocyte functions in severely injured type A- glucose-6-phosphate dehydrogenase-deficient African American trauma patients. Crit Care Med 2001;29:728-36.
89. Roos D, van Zwieten R, Wijnen JT et al. Molecular basis and enzymatic properties of glucose 6-phosphate dehydrogenase volendam, leading to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 1999;94:2955-62.
90. Agudelo-Florez P, Costa-Carvalho BT, Lopez JA et al. Association of glucose-6-phosphate dehydrogenase deficiency and X-linked chronic granulomatous disease in a child with anemia and recurrent infections. Am J Hematol 2004;75:151-6.
91. Frank JE. Diagnosis and management of G6PD deficiency. Am Fam Physician 2005;72:1277-82.
92. Marques OC, Frazao JB, Pereira PV et al. Neutrophils and monocytes from patients with CD40L deficiency present a defective respiratory burst response to several stimuli and this defect can be reversed by exogenous IFN-gamma. Clin Immunol 2010;135:296-7.
93. Filipe-Santos O, Bustamante J, Chapgier A et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 2006;18 (6):347-61.Epub 2006 Sep 25. Review. Erratum in: Semin Immunol. 2007; 19:136-7.
94. Condino-Neto A, Prando C, Aragao-Filho WC et al. Defects of IFN-gamma Receptors 1 and 2 impair the phagocytic nadph oxidase function and CYBB, CYBA, and NCFL gene expression. Clin Exp Immunol 2008;154:8-9.
95. Bustamante J, Vogt G, Blancas-Galicia L et al. A germline but macrophage-tropic CYBB mutation in patients with X-linked predisposition to mycobacterial diseases. Clin Exp Immunol 2008;154:10.